Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Robert Knight who wrote (719)	7/2/1998 7:16:00 AM
From: AHM	Read Replies (2) \| Respond to of 1510

If shorts are growing, it may not be "Market Maker manipulations" that most postings on this board are implying. Instead, it may give rise to concern for those who are long. Why would short positions grow? Only one reason that I can think of. Those investors doubt that the expected news from IMNR will not be as spectacular as the longs believe it will be. A posting on Yahoo in response to a message that cited statistical evidence that was highly impressive noted that statistically the data had little "power". By that, the message went on to note that "power" in statistics is a measure of the sample size. When the sample is small, the data may not prove to be reliable as the sample enlarges in size. For both longs and shorts the contents and reactions to IMNR's scheduled poster presentation by Dr. Valentine tomorrow represents a major divergence of opinion on which huge amounts of money are being placed at risk by bulls and bears. The longs are no smarter than the shorts. Who will be the winner won't really be known until Monday when the market reopens.

To: Robert Knight who wrote (719)	7/2/1998 8:06:00 AM
From: Emec	Read Replies (1) \| Respond to of 1510

<- Previous Next -> Message 2232 of 2234 Reply Immune Response AIDS Therapy Boosts Immune Cells in Early RUSH__2000 Jul 2 1998 7:53AM EDT Geneva, July 2 (Bloomberg) - Immune Response Corp.'s AIDS therapy, Remune, developed in part by the late Jonas Salk, appears to help reduce the amount of HIV in the blood, early research shows. Preliminary results of a 43-patient study were presented at the 12th World AIDS Conference in Geneva. Remune is intended to stimulate the immune system to attack HIV. In 18 of 21 patients, or 86 percent, the amount of HIV in the blood dropped to fewer than 40 copies a milliliter. In the group that received only AZT, 3TC and Crixivan, 12 out of 18, or 16 percent, had the same success in treatment. At the start of the test, the median count of HIV in the blood was 8,159 copies. ''Although it's preliminary, it's promising,'' said Elise Wang, an analyst with PaineWebber Inc., after a presentation on the study in Geneva this morning. Wang has a ''buy'' rating on Agouron Pharmaceuticals Inc., which is working with Immune Response on the drug. Agouron, maker of the AIDS drug, Viracept, could give Immune Response as much as $77 million in a pact for the development and marketing of Remune. Remune is in late-stage testing. If these results are these studies are positive, Immune Response could apply to the U.S. Food and Drug Administration for approval of the drug in mid 1999, the company said. Immune Response fell 1 1/4 yesterday to 13 3/4. IMNR: Quote \| Profile \| Research This Is a Reply to: Msg 2230 by betthepharm View Replies to this Message